About Arnivas 50 24 mg + 26 mg Tablet
Arnivas 50 comes as a tablet with 24 mg + 26 mg of Sacubitril + Valsartan, from Opsonin Pharma Limited. Arnivas 50 is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure and reduced ejection fraction.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. 3 of them have a lower unit price than Arnivas 50. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is Arnivas 50 24 mg + 26 mg Tablet?
Arnivas 50 24 mg + 26 mg is a tablet product of Opsonin Pharma Limited that contains Sacubitril + Valsartan. Together they work on the heart and blood vessels to support heart function in heart failure. The same combination is also used to treat symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Whether it suits you is a decision for your doctor.
Uses of Arnivas 50
Arnivas 50 is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure and reduced ejection fraction. It helps lower the risk of dying from heart problems and reduces the chance of needing hospital care for heart failure. The doctor decides whether it is suitable, based on the patient's condition and other medicines being taken.
How to use Arnivas 50
Take Arnivas 50 as the doctor prescribes. Swallow the tablet with water. Arnivas 50 is taken by mouth. Take Arnivas 50 24 mg + 26 mg tablet by mouth as directed by your doctor. Do not change the dose or stop early without asking your doctor. The doctor decides the dose and course.
Side effects of Arnivas 50
Call your doctor right away if you have swelling of the face, lips, tongue, or throat, difficulty breathing, or if you feel very dizzy or faint. Your doctor may monitor your kidney function and potassium levels during treatment. Angioedema is serious and needs immediate medical attention. Tell your doctor or pharmacist if you notice any side effects or if they bother you. Tell your doctor if you feel very dizzy or faint, or pass much less urine than usual.
Safety and precautions
Do not take this medicine if you have had angioedema related to an ACE inhibitor or ARB, or if you have hereditary angioedema. Elderly patients can take it without dose adjustment. Arnivas 50 is not safe during pregnancy because it can harm the unborn baby. Tell your doctor about any previous swelling of the face, lips or throat, especially linked to heart or blood-pressure medicines, and about kidney or liver problems.
Frequently asked questions
What is Arnivas 50 used for?
Arnivas 50 is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure and reduced ejection fraction. It helps lower the risk of dying from heart problems and reduces the chance of needing hospital care for heart failure.
How do I use Arnivas 50 correctly?
Take Arnivas 50 as the doctor prescribes. Swallow the tablet with water.
What are the side effects of Arnivas 50?
Call your doctor right away if you have swelling of the face, lips, tongue, or throat, difficulty breathing, or if you feel very dizzy or faint. Your doctor may monitor your kidney function and potassium levels during treatment.
Is Arnivas 50 safe for everyone?
Do not take this medicine if you have had angioedema related to an ACE inhibitor or ARB, or if you have hereditary angioedema. Elderly patients can take it without dose adjustment.
- Strength
- 24 mg + 26 mg
Price in Bangladesh
৳ 44.1 ৳ 45 2% off unit price
Price updated: 16 Nov 2026
Indications
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
... Read more
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.
Dosage & Administration
Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.
Recommended Dose Titration-Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
Pediatric Patients At least 50 kg:
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
This combination is contraindicated:
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.
Pregnancy & Lactation
Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.
Storage Conditions
Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
See all 25 brands
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.